The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a brand name biological product. The guidance focuses on therapeutic protein products, one category of biological product. The Biologics Price Competition and Innovation Act of 2009 created an abbreviated licensure pathway for biosimilar products in an effort to increase competition for biological products and lower costs. Depending on state law, a biosimilar product that is interchangeable may be substituted for a brand name biological product at the pharmacy without the involvement of the prescriber, similar to how generic drugs are substituted for brand name drugs. Beginning next March under the BPCI Act, insulin products will be deemed biological products, meaning the guidance may also help biosimilar and interchangeable insulin products come to market.   
 

Related News Articles

Headline
Hospitals spend close to $360 million each year to manage drug shortages, according to a study released this week by Vizient Inc.
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.